Therapeutic Drugs For The Treatment Of Nephrogenic Diabetes Insipidus (ndi)

A new use for drugs such as Plavix® or Brilinta® ameliorates polyuria of acquired NDI by pharmacological blockade of P2Y12 receptor.

Currently used therapies for acquired NDI are associated with varying degrees of success as well as adverse effects, especially in the elderly and critically ill patients, and contribute to complications in patients with coronary or cerebral arterial diseases.

The most common cause of NDI is the use of lithium for the treatment of bipolar disorder (BD). Despite the advent of newer drugs for BD, lithium is still an important medication in the psychiatric treatment regimen by virtue of the significantly lower suicidal risk in lithium-treated patients. This invention demonstrates that administration of Plavix® significantly reduces lithium-induced polyuria in rats and is associated with a significant restoration of lithium-induced decrease in AQP2 protein.

Lead Identified

• The P2Y12 receptor blocking drugs have been in the market for quite a few years, and they have been well tolerated with fewer side effects as compared to the current therapies for NDI
• Dual purpose: Prevents the complications of coronary, cerebral arterial or peripheral vascular diseases in addition to treating NDI symptoms
• Limits the number of drugs to be used for co-morbid conditions, minimizing side effects
• Uses currently available specific drugs in the market and no further safety studies are required for their use in NDI

Zhang, Yue et al. “Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice.” Purinergic signalling vol. 13,2 (2017): 239-248. doi:10.1007/s11302-017-9555-6

Publication Number: US-2014-0377380
Patent Title: Methods and Compositions for Treating Nephorgenic Diabetes Insipidus
Jurisdiction/Country: United States
Application Type: Non-Provisional

Steven Christiansen
801.587.0915
steven.christiansen@utah.edu